Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Technology Scientific & Technical Instruments
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Sona Nanotech Inc > Clinical Trials To Begin For Sona Nanotech’s COVID-19 Rapid
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1206)
•••
Comment by Moemoney42on Apr 23, 2021 10:05am
137 Views
Post# 33054494

RE:Clinical Trials To Begin For Sona Nanotech’s COVID-19 Rapid

RE:Clinical Trials To Begin For Sona Nanotech’s COVID-19 Rapid
AwareInvestor wrote:
Sona Nanotech Inc. announced after market close last night that it has received the go signal from the research ethics board to proceed with the previously approved clinical trials for its saliva-based COVID-19 rapid antigen test. The trials are expected to begin next week.

This news although long overdue is great and should propel the stock over $2 today..One would hope that the long development time line has given SONA the ability to fine tune the test so that its nearly guaranteed approval... could be good news by the end of the month... if not, definately next month... ;-)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities